What happened
Samsung Biologics disclosed an acquisition of Samsung Biologics America, Inc., worth US$352M.
For context, this deal is worth about 4.8% of the company's own total assets.
| Target | Samsung Biologics America, Inc. |
|---|---|
| Deal value | US$352M |
| vs. company assets | 4.8% |
| Filed | 2026-03-20, Decision to acquire shares/equity in another company |
| Source | DART rcept 20260320801891 → open original filing |
Source: DART. Information only, not investment advice.